Petrel Christophe, Kessler Albane, Dauban Philippe, Dodd Robert H, Rognan Didier, Ruat Martial
Institut de Neurobiologie Alfred Fessard, IFR 2118 CNRS, Laboratoire de Neurobiologie Cellulaire et Moléculaire, UPR 9040 CNRS, Bâtiment 33, 1 avenue de la terrasse, 91198 Gif sur Yvette, France.
J Biol Chem. 2004 Apr 30;279(18):18990-7. doi: 10.1074/jbc.M400724200. Epub 2004 Feb 19.
A three-dimensional model of the human extracellular Ca(2+)-sensing receptor (CaSR) has been used to identify specific residues implicated in the recognition of two negative allosteric CaSR modulators of different chemical structure, NPS 2143 and Calhex 231. To demonstrate the involvement of these residues, we have analyzed dose-inhibition response curves for the effect of these calcilytics on Ca(2+)-induced [(3)H]inositol phosphate accumulation for the selected CaSR mutants transiently expressed in HEK293 cells. These mutants were further used for investigating the binding pocket of two chemically unrelated positive allosteric CaSR modulators, NPS R-568 and (R)-2-[1-(1-naphthyl)ethylaminomethyl]-1H-indole (Calindol), a novel potent calcimimetic that stimulates (EC(50) = 0.31 microM) increases in [(3)H]inositol phosphate levels elicited by activating the wild-type CaSR by 2 mM Ca(2+). Our data validate the involvement of Trp-818(6.48), Phe-821(6.51), Glu-837(7.39), and Ile-841(7.43) located in transmembranes (TM) 6 and TM7, in the binding pocket for both calcimimetics and calcilytics, despite important differences observed between each family of compounds. The TMs involved in the recognition of both calcilytics include residues located in TM3 (Arg-680(3.28), Phe-684(3.32), and Phe-688(3.36)). However, our study indicates subtle differences between the binding of these two compounds. Importantly, the observation that some mutations that have no effect on calcimimetics recognition but which affect the binding of calcilytics in TM3 and TM5, suggests that the binding pocket of positive and negative allosteric modulators is partially overlapping but not identical. Our CaSR model should facilitate the development of novel drugs of this important therapeutic target and the identification of the molecular determinants involved in the binding of allosteric modulators of class 3 G-protein-coupled receptors.
利用人细胞外钙敏感受体(CaSR)的三维模型,确定了与两种化学结构不同的负性变构CaSR调节剂NPS 2143和Calhex 231识别相关的特定残基。为了证明这些残基的作用,我们分析了这些钙解敏剂对在HEK293细胞中瞬时表达的选定CaSR突变体的Ca(2+)诱导的[(3)H]肌醇磷酸积累的剂量抑制反应曲线。这些突变体还用于研究两种化学结构不相关的正性变构CaSR调节剂NPS R-568和(R)-2-[1-(1-萘基)乙氨基甲基]-1H-吲哚(Calindol)的结合口袋,Calindol是一种新型强效钙敏化剂,可刺激(EC(50)=0.31 microM)由2 mM Ca(2+)激活野生型CaSR引起的[(3)H]肌醇磷酸水平升高。我们的数据证实了位于跨膜区(TM)6和TM7的Trp-818(6.48)、Phe-821(6.51)、Glu-837(7.39)和Ile-841(7.43)参与了钙敏化剂和钙解敏剂的结合口袋,尽管在每类化合物之间观察到重要差异。参与识别两种钙解敏剂的跨膜区包括位于TM3的残基(Arg-680(3.28)、Phe-684(3.32)和Phe-688(3.36))。然而,我们的研究表明这两种化合物的结合存在细微差异。重要的是,一些对钙敏化剂识别无影响但影响TM3和TM5中钙解敏剂结合的突变的观察结果表明,正性和负性变构调节剂的结合口袋部分重叠但不相同。我们的CaSR模型应有助于开发针对这一重要治疗靶点的新型药物,并确定参与3类G蛋白偶联受体变构调节剂结合的分子决定因素。